References
- Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention. 2020. https://ginasthma.org.
- Loureiro CC, Amaral L, Ferreira JA, et al. Omalizumab for severe
asthma: beyond allergic asthma. Biomed Res Int.2018;2018:3254094.
- Celebi Sozener Z, Aydin O, Misirligil Z, et al. Omalizumab in
non-allergic asthma: a report of 13 cases. J Asthma.2018;55(7):756-763.
- Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM.
Effectiveness of omalizumab in non-allergic severe asthma. J
Biol Regul Homeost Agents. 2013;27(1):45-53.
- Campo Mozo P, Soto-Campos JG, Blanco Aparicio M, et al. Severe asthma
phenotypes in patients controlled with omalizumab: a real-world study.
Respir Med.2019; 159; 105804.
- de Llano LP, Vennera MdC, Álvarez FJ, et al. Effects of omalizumab in
non-atopic asthma: results from a Spanish Multicenter Registry.J Asthma. 2013;50(3):296-301.
- Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE
for intrinsic asthma? Thorax. 2014;69(1):94-96.
- Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized,
controlled trial of omalizumab in patients with severe,
difficult-to-control, nonatopic asthma. Chest.2013;144(2):411-419.
- Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal
IgE and improves lung function in non-atopic asthma. Eur Respir
J. 2016;48(6):1593-1601.